Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (24)

Advertisement

Research Article Free access | 10.1172/JCI109446

Serum Inhibitor of C5 Fragment-Mediated Polymorphonuclear Leukocyte Chemotaxis Associated with Chronic Hemodialysis

Simeon E. Goldblum, Dennis E. Van Epps, and William P. Reed

Department of Medicine, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Department of Microbiology, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Find articles by Goldblum, S. in: PubMed | Google Scholar

Department of Medicine, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Department of Microbiology, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Find articles by Van Epps, D. in: PubMed | Google Scholar

Department of Medicine, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Department of Microbiology, Veterans Administration Hospital and University of New Mexico School of Medicine, Albuquerque, New Mexico 87108

Find articles by Reed, W. in: PubMed | Google Scholar

Published July 1, 1979 - More info

Published in Volume 64, Issue 1 on July 1, 1979
J Clin Invest. 1979;64(1):255–264. https://doi.org/10.1172/JCI109446.
© 1979 The American Society for Clinical Investigation
Published July 1, 1979 - Version history
View PDF
Abstract

Abnormal granulocyte chemotaxis has been described in chronic hemodialysis patients. In this study, sera from 53 hemodialysis patients were tested for chemotactic inhibitory activity by a modified Boyden technique. Chemotactic inhibitory activity, defined as >20% inhibition of normal granulocyte chemotaxis, was found in 45% of patients. Only sera from patients having undergone >3 mo hemodialysis displayed chemotactic inhibitory activity and retained this inhibitory activity when retested 9 mo later. Four of five patients who had initially undergone <3 mo hemodialysis and lacked serum chemotactic inhibitory activity developed inhibitory activity when tested 9 mo later. Clinical evaluation of patients with serum chemotactic inhibitory activity showed that these patients did not have a significantly increased incidence of infection, although a trend toward decreased mortality during the time of study was observed (P = 0.0721).

Serum chemotactic inhibitory activity was heat stable at 56°C for 30 min and concentration dependent. The major inhibitory component was found to have a sedimentation coefficient of 4S by sucrose density gradient centrifugation. The chemotactic inhibitory activity was not precipitated by 30% ammonium sulfate, but was partially precipitated by 50% ammonium sulfate.

Inhibitory sera effectively suppressed neutrophil migration in response to chemotactic C5 fragment and Escherichia coli derived chemotactic factor but was least effective in a system mediated by casein. Furthermore, normal neutrophils preincubated in hemodialysis patient sera displayed normal chemotactic responsiveness indicating a lack of cell-directed inhibition. Serum fractions that contained the inhibitor were found to directly act on the chemotactic C5 fragment, reducing its chemotactic activity. This study indicates that a circulating 4S, heat-stable, factor-directed inhibitor of granulocyte chemotaxis is present in the sera of many hemodialysis patients and probably results from the hemodialysis procedure.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 255
page 255
icon of scanned page 256
page 256
icon of scanned page 257
page 257
icon of scanned page 258
page 258
icon of scanned page 259
page 259
icon of scanned page 260
page 260
icon of scanned page 261
page 261
icon of scanned page 262
page 262
icon of scanned page 263
page 263
icon of scanned page 264
page 264
Version history
  • Version 1 (July 1, 1979): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (24)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts